MetaVia Inc. filed a Form 8-K with the SEC on October 28, 2026, disclosing that an abstract of Phase 1 clinical trial data for its drug candidate DA-1726 has been accepted for an oral presentation at the Precision Liver Symposium 2026.

Key Highlights

  • Drug candidate: DA-1726 is described in the filing as "a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors."
  • Presentation type: The abstract has been accepted for an oral presentation, according to the filing.
  • Conference: The presentation is scheduled at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado.
  • Data source: The abstract highlights data from the Phase 1 clinical trial of DA-1726, the filing states.
  • Filing basis: The disclosure was made under Regulation FD and the information is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934.

MetaVia Discloses DA-1726 Phase 1 Abstract Acceptance Under Regulation FD

MetaVia Inc. (NASDAQ:MTVA), headquartered at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, issued a press release on October 28, 2026, announcing that an abstract featuring Phase 1 clinical trial data for DA-1726 had been accepted for oral presentation. The company filed a Form 8-K on the same date to satisfy its Regulation FD disclosure obligations, attaching the press release as Exhibit 99.1.

According to the filing, DA-1726 is characterized as "a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors." The oral presentation is set to take place at the Precision Liver Symposium 2026, scheduled for November 4, 2026, in Denver, Colorado. The filing does not include the underlying clinical data itself; that information is contained in the press release incorporated by reference.

The filing notes that the information furnished under Item 7.01, including the attached press release, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not subject to that section's liabilities. The company also stated that its submission "shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD." The report was signed by Hyung Heon Kim, President and Chief Executive Officer.

What Was Disclosed

MetaVia Inc. reported via an 8-K filed October 28, 2026, that Phase 1 trial data for DA-1726, a dual GLP-1R and GCGR receptor analog, has been accepted for an oral presentation at the Precision Liver Symposium 2026 on November 4, 2026, in Denver, Colorado.